YSB Inc. (HK:9885)
:9885
Want to see HK:9885 full AI Analyst Report?
Top Page
YSB Inc.
(9885)
Select Model
Select Model
Rating:61Neutral
Price Target:
HK$6.00
▲(16.28% Upside)
Action:N/ADate:04/26/26
The score is primarily driven by improving financial performance—revenue growth, a 2025 return to profitability, and consistently positive, growing free cash flow—balanced by elevated balance-sheet risk from higher 2025 leverage and very thin margins. Technicals are supportive in the near term with positive momentum, while valuation is only moderate given the current earnings quality and modest dividend yield.
Positive Factors
Consistent positive free cash flow
YSB's multi-year positive free cash flow, including ~27% FCF growth in 2025, creates durable internal funding. That reduces reliance on external financing, supports debt servicing and reinvestment in product and sales, and lends credibility to reported profits amid narrow margins.
Negative Factors
Very thin operating and net margins
Gross margin near 11% and net margin below 1% are unusually thin for an application-software firm. Low margins leave earnings highly sensitive to cost increases, pricing pressure or customer churn, limiting the company's ability to generate high returns and making long-term profitability fragile.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent positive free cash flow
YSB's multi-year positive free cash flow, including ~27% FCF growth in 2025, creates durable internal funding. That reduces reliance on external financing, supports debt servicing and reinvestment in product and sales, and lends credibility to reported profits amid narrow margins.
Read all positive factors
YSB Inc. (9885) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.90B
Dividend Yield1.38%
Average Volume (3M)9.20M
Price to Earnings (P/E)22.1
Beta (1Y)0.76
Revenue Growth17.22%
EPS Growth385.91%
CountryHK
Employees6,763
SectorHealthcare
Sector Strength45
IndustrySoftware - Application
Share Statistics
EPS (TTM)0.12
Shares Outstanding688,070,900
10 Day Avg. Volume7,414,414
30 Day Avg. Volume9,200,413
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.35
Price to Sales (P/S)0.16
P/FCF Ratio5.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.38
Revenue Forecast (FY)HK$23.46B
YSB Inc. Business Overview & Revenue Model
Company Description
YSB Inc. develops digital pharmaceutical platform for pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions in China. It develops ClouDiagnos for diagnostic testing service; wePharmacy, a 24-hour access s...
YSB Inc. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
49
Neutral
Cash Flow
72
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.43B | 17.90B | 16.97B | 14.27B | 10.09B |
| Gross Profit | 2.25B | 1.81B | 1.74B | 1.43B | 913.83M |
| EBITDA | 210.27M | -42.13M | -3.07B | -1.35B | -392.32M |
| Net Income | 149.01M | 30.01M | -3.21B | -1.50B | -501.62M |
Balance Sheet | |||||
| Total Assets | 7.57B | 6.50B | 5.21B | 4.11B | 3.44B |
| Cash, Cash Equivalents and Short-Term Investments | 3.38B | 1.99B | 1.83B | 1.87B | 1.14B |
| Total Debt | 2.77B | 233.51M | 209.66M | 180.55M | 181.73M |
| Total Liabilities | 5.18B | 4.23B | 3.33B | 8.48B | 6.35B |
| Stockholders Equity | 2.44B | 2.32B | 1.92B | -4.35B | -2.90B |
Cash Flow | |||||
| Free Cash Flow | 619.46M | 632.46M | 433.65M | 54.49M | -608.06M |
| Operating Cash Flow | 637.70M | 655.86M | 451.20M | 98.20M | -487.09M |
| Investing Cash Flow | -896.27M | -253.58M | -792.95M | 41.07M | -352.80M |
| Financing Cash Flow | -70.97M | -109.81M | 255.34M | 261.93M | 1.12B |
YSB Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$376.45M | 4.98 | 4.28% | 7.10% | -2.78% | -24.77% | |
64 Neutral | HK$158.97M | 5.31 | 6.92% | 8.00% | -17.36% | -29.80% | |
61 Neutral | HK$3.90B | 22.10 | 6.36% | 1.38% | 17.22% | 385.91% | |
54 Neutral | HK$236.91M | 15.20 | 2.98% | 28.00% | 25.18% | 245.83% | |
52 Neutral | HK$307.44M | 4.11 | 3.54% | 3.75% | 9.74% | 32.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$76.13M | -4.87 | -27.01% | ― | -5.97% | -1594.12% |
* Healthcare Sector Average
HK:9885
YSB Inc.
5.37
-0.91
-14.49%
HK:1419
Human Health Holdings Ltd.
0.81
0.05
6.58%
HK:2293
Bamboos Health Care Holdings Ltd
0.40
-0.17
-29.46%
HK:3390
Tycoon Group Holdings Limited
0.27
-0.15
-36.90%
HK:0722
UMP Healthcare Holdings Limited
0.46
0.09
25.00%
HK:8357
Republic Healthcare Limited
0.12
0.02
25.77%
YSB Inc. Corporate Events
YSB Inc. Sets 2026 AGM to Approve Dividend, Board Changes and Share Mandates
Apr 23, 2026
YSB Inc. has called its annual general meeting for 21 May 2026 in Guangzhou, where shareholders will review the audited financial statements for the year ended 31 December 2025 and vote on a proposed final dividend of RMB0.110 per share. Investors...
YSB Inc. Awards Over 32 Million Share Options to Top Executives Under 2023 Incentive Plan
Mar 24, 2026
YSB Inc. has granted a total of 32,551,518 share options to two senior executives under its 2023 Share Incentive Plan, signaling a substantial equity-based reward for top management. The options, tied to existing shares acquired on the market by a...
YSB Inc. Hits 2025 Earn-Out Targets on Strategic Acquisition and Issues Contingent Shares
Mar 23, 2026
YSB Inc. reported strong progress on its previously announced acquisition of a target company, noting that integration has advanced effectively and resource reuse and channel synergies are yielding concrete results in line with expectations. The c...
YSB Inc. Declares Final 2025 Cash Dividend for Hong Kong Shareholders
Mar 23, 2026
YSB Inc. has proposed a final ordinary cash dividend of RMB 0.11 per share for the financial year ended 31 December 2025, equivalent to HKD 0.125 per share based on an exchange rate of RMB 1 to HKD 1.137. The payout, subject to shareholder approva...
YSB Inc. posts strong 2025 earnings as digital pharma platform strategy pays off
Mar 23, 2026
YSB Inc. reported robust results for 2025, with revenue rising 17.1% year on year to RMB20.97 billion, driven mainly by an 18.2% increase in its self-operation business while online marketplace revenue dipped slightly. Gross profit climbed 27.2% t...
YSB Inc. Schedules Board Meeting to Approve 2025 Annual Results and Consider Final Dividend
Mar 11, 2026
YSB Inc. has announced that its board of directors will convene on 23 March 2026 to review and approve the group’s audited annual results for the financial year ended 31 December 2025. The meeting will also consider the publication of these ...
YSB Inc. Awards 2.53 Million Shares to Employees Under 2023 Incentive Plan
Feb 10, 2026
YSB Inc. has granted 2,533,700 new shares, equivalent to about 0.37% of its issued share capital, to 415 employee participants under its 2023 Share Incentive Plan at no purchase price, with the grant date set as 10 February 2026 and a reference cl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.